Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial (2013)
Journal Article
Ford, H., Marshall, A., Bridgewater, J. A., Janowitz, T., Coxon, F., Wadsley, J., …Dunn, J. A. (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, 15(1), https://doi.org/10.1016/S1470-2045%2813%2970549-7

BACKGROUND: Second-line chemotherapy for patients with oesophagogastric adenocarcinoma refractory to platinum and fluoropyrimidines has not shown benefits in health-related quality of life (HRQoL). We assessed whether the addition of docetaxel to act... Read More about Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays (2013)
Journal Article
Tewari, N., Zaitoun, A. M., Arora, A., Madhusudan, S., Ilyas, M., & Lobo, D. N. (2013). The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays. BMC Cancer, 13, Article 436. https://doi.org/10.1186/1471-2407-13-436

Background Tumour-associated lymphocytes (TALs) have been linked with good prognosis in several solid tumours. This study aimed to evaluate the prognostic significance of CD3, CD8 and CD20 positive lymphocytes in pancreatic ductal adenocarcinoma.... Read More about The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.

Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer? (2013)
Journal Article
Abdel-Fatah, T., Arora, A., Gorguc, I., Abbotts, R., Beebeejaun, S., Storr, S. J., …Madhusudan, S. (2013). Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?. Antioxidants and Redox Signaling, 18(18), https://doi.org/10.1089/ars.2012.4873

Chronic inflammation is a driving force for gastric carcinogenesis. Reactive oxygen species (ROS) generated during the inflammatory process generates DNA damage that is processed through the DNA repair pathways. In this study, we profiled key DNA rep... Read More about Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?.

Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells (2013)
Journal Article
Sultana, R., Abdel-Fatah, T., Perry, C., Moseley, P., Albarakti, N., Mohan, V., …Madhusudan, S. (2013). Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS ONE, 8(2), Article e57098. https://doi.org/10.1371/journal.pone.0057098

Introduction Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is a key sensor of single-stranded DNA associated with stalled replication forks and repair intermediates generated during DNA repair. XRCC1 is a critical enzyme in sin... Read More about Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.